Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anti-Allergy Medicine Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The anti-allergy medicine market has experienced robust expansion recently. It is projected to expand from $42.25 billion in 2025 to $45.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.7%. Historically, this growth has been driven by factors such as seasonal allergies, urban pollution, over-the-counter drug access, hospital allergy treatment, and the availability of antihistamines.
The anti-allergy medicine market size is poised for substantial growth over the next few years. It is projected to reach $63.27 billion in 2030, with a compound annual growth rate (CAGR) of 8.3%. This expansion during the forecast period can be attributed to factors such as an increase in climate-related allergies, the development of digital pharmacies, advancements in biologic allergy treatments, heightened pediatric allergy awareness, and the broadening of healthcare access. Major trends expected in the forecast period include the rising prevalence of allergic conditions, the increasing availability of over-the-counter (OTC) allergy medications, greater adoption of second-generation antihistamines, the expansion of online pharmacy sales, and a focus on formulations tailored for pediatric and geriatric populations.
Get A Free Sample Report With In-Depth Market Insights:
Anti-Allergy Medicine Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing incidence of allergies is anticipated to drive expansion in the anti-allergy medicine market moving ahead. Allergies are characterized by an overactive immune system’s reaction to substances like pollen, dust mites, certain foods, or pet dander, leading to symptoms that vary from minor discomfort to serious, potentially fatal responses. These conditions encompass hay fever, asthma, eczema, food allergies, and allergic rhinitis. The rising occurrence of allergies can be attributed to increased environmental contamination, since pollutants compromise the immune system and boost susceptibility to everyday allergens. Anti-allergy medicines assist in managing allergic reactions by offering specific relief from allergens, thus becoming crucial for people suffering from conditions like hay fever, asthma, and eczema. These medications mitigate excessive immune responses by inhibiting histamines and other instigators, thereby enhancing daily comfort and overall quality of life. For instance, in May 2025, according to the UK Parliament, a UK-based government body, there were 3,886,879 people over the age of six diagnosed with asthma in 2023-24, accounting for 6.5% of England’s population. Consequently, the expanding prevalence of allergies is fueling the growth of the anti-allergy medicine market.
Anti-Allergy Medicine Market Segmentation And Category Overview
The anti-allergy medicine market covered in this report is segmented –
1) By Drug Class: Antihistamines, Corticosteroids, Decongestants, Leukotriene Inhibitors, Mast Cell Stabilizers, Other Drug Classes
2) By Type Of Allergy: Seasonal Allergies, Perennial Allergies, Food Allergies, Skin Allergies, Insect Sting Allergies
3) By Formulation: Tablets, Capsules, Syrups, Nasal Sprays, Eye Drops, Injectables
4) By Application: Online Pharmacy, Hospital, Offline Pharmacy, Clinic, Other Applications
5) By End User: Children, Adults, Geriatric Population, Pregnant Women
Subsegments:
1) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines, Third-Generation Antihistamines
2) By Corticosteroids: Oral Corticosteroids, Nasal Corticosteroids, Inhaled Corticosteroids, Topical Corticosteroids
3) By Decongestants: Oral Decongestants, Nasal Spray Decongestants, Topical Decongestants
4) By Leukotriene Inhibitors: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors
5) By Mast Cell Stabilizers: Cromolyn Sodium, Nedocromil Sodium
6) By Other Drug Classes: Immunotherapy Agents, Biologics, Monoclonal Antibodies
Anti-Allergy Medicine Market Innovation Trends Shaping Future Development
Leading companies in the anti-allergy medicine market are concentrating on creating novel therapies and securing regulatory approvals, such as monoclonal antibody treatments, to offer targeted care, enhance effectiveness, lessen adverse effects, and tackle chronic and severe allergic ailments. Monoclonal antibody therapies are laboratory-produced proteins designed to replicate the immune system’s capacity to combat detrimental allergens by specifically targeting and obstructing immune pathways implicated in allergic responses, thus providing accurate and durable relief. For example, in December 2024, Galderma SA, a pharmaceutical company based in Switzerland, gained approval from the Food and Drug Administration (FDA) for Nemluvio (nemolizumab-ilto) for use in treating adults and pediatric patients aged 12 years and older with moderate to severe atopic dermatitis when combined with topical corticosteroids and/or calcineurin inhibitors. This monoclonal antibody acts as an interleukin-31 receptor antagonist, functioning by blocking IL-31 signaling, a critical factor in inflammation and itching associated with atopic dermatitis, thereby reducing symptoms and improving skin health.
Anti-Allergy Medicine Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the anti-allergy medicine market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Perrigo Company plc, Cipla Limited, Dr. Reddy’s Laboratories, Lupin Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd., ALK-Abelló A/S, Torii Pharmaceutical Co. Ltd., Biomay Aktiengesellschaft, Kaléo Inc., Immunomic Therapeutics Inc., Circassia Group plc, Sun Pharmaceutical Industries Ltd., Anergis S.A., Aravax Pty Ltd., DBV Technologies S.A., Desentum Oy.
View The Full Anti-Allergy Medicine Market Report:
Anti-Allergy Medicine Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the anti-allergy medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-allergy medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model